The optimal time for hematopoietic stem cell translantation for Hodgkin''s lymphoma. International guidelines and real practic in Russia and former USSSR countries (Part II)
The worst results (p < 0.05) are in patients who have received > 2 lines of therapy prior HSCT (5-year OS - 46 ± 9.7 %, FFTF - 38.4 ± 9.0 %). The negative impact of previous treatment on the efficiency of hematopoietic material collection and hematopoiesis reconstitution as well observed in patients who received > 2 lines of therapy. Therefore, if the delay of HSCT in patients who achieved remission on second- line therapy was caused by organizational problems, for optimum results is necessary to conduct HSCT not later than second relapse while maintaining tumor chemosensitivity (third disease remission). However, when remission is not achieved after second-line therapy, is neces- sary to change the treatment regimen and performing HSCT only at confirmation of tumor chemosensitivity, because regardless of prior therapy line number, this approach leads to better results than earlier performing HSCT without remission.